191 related articles for article (PubMed ID: 11809703)
21. Down-regulation of fragile histidine triad expression in prostate carcinoma.
Fouts RL; Sandusky GE; Zhang S; Eckert GJ; Koch MO; Ulbright TM; Eble JN; Cheng L
Cancer; 2003 Mar; 97(6):1447-52. PubMed ID: 12627509
[TBL] [Abstract][Full Text] [Related]
22. Expression and prognostic value of the lung resistance-related protein (LRP) in germ cell testicular tumors.
Mándoky L; Géczi L; Doleschall Z; Bodrogi I; Csuka O; Kásler M; Bak M
Anticancer Res; 2004; 24(2C):1097-104. PubMed ID: 15154630
[TBL] [Abstract][Full Text] [Related]
23. Abnormal transcripts of FHIT gene in thyroid cancer.
Chang TJ; Tsai TC; Wu YL; Yang HM; Chi CW; Yang AH; Lee CH
Oncol Rep; 1998; 5(1):245-7. PubMed ID: 9458330
[TBL] [Abstract][Full Text] [Related]
24. Molecular analysis of the FHIT gene in human prostate cancer.
Latil A; Bièche I; Fournier G; Cussenot O; Pesche S; Lidereau R
Oncogene; 1998 Apr; 16(14):1863-8. PubMed ID: 9583683
[TBL] [Abstract][Full Text] [Related]
25. The fragile histidine triad gene: a molecular link between cigarette smoking and cervical cancer.
Holschneider CH; Baldwin RL; Tumber K; Aoyama C; Karlan BY
Clin Cancer Res; 2005 Aug; 11(16):5756-63. PubMed ID: 16115913
[TBL] [Abstract][Full Text] [Related]
26. The Fragile Histidine Triad gene and breast cancer.
Yang Q; Yoshimura G; Sakurai T; Kakudo K
Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
[TBL] [Abstract][Full Text] [Related]
27. Molecular genetic changes in human male germ cell tumors.
Lothe RA; Peltomäki P; Tommerup N; Fosså SD; Stenwig AE; Børresen AL; Nesland JM
Lab Invest; 1995 Nov; 73(5):606-14. PubMed ID: 7474934
[TBL] [Abstract][Full Text] [Related]
28. Molecular analysis of the fragile histidine triad (FHIT) tumor suppressor gene in vesical tumors of cattle with chronic enzootic hematuria (CEH).
Guidi E; Uboldi C; Ferretti L
Cytogenet Genome Res; 2008; 120(1-2):173-7. PubMed ID: 18467844
[TBL] [Abstract][Full Text] [Related]
29. Concordant loss of fragile gene expression early in breast cancer development.
Guler G; Uner A; Guler N; Han SY; Iliopoulos D; McCue P; Huebner K
Pathol Int; 2005 Aug; 55(8):471-8. PubMed ID: 15998374
[TBL] [Abstract][Full Text] [Related]
30. Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development.
Lea JS; Ashfaq R; Muneer S; Burbee DG; Miller DS; Minna JD; Muller CY
J Soc Gynecol Investig; 2004 Jul; 11(5):329-37. PubMed ID: 15219888
[TBL] [Abstract][Full Text] [Related]
31. Analysis of FHIT allelic imbalance/loss of heterozygosity and FHIT expression in cutaneous squamous cell carcinomas.
Gray SE; Kay E; Leader M; Mabruk M
J Cutan Pathol; 2008 Sep; 35(9):816-25. PubMed ID: 18494825
[TBL] [Abstract][Full Text] [Related]
32. FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines.
Hendricks DT; Taylor R; Reed M; Birrer MJ
Cancer Res; 1997 Jun; 57(11):2112-5. PubMed ID: 9187105
[TBL] [Abstract][Full Text] [Related]
33. Frequent aberration of FHIT gene expression in acute leukemias.
Iwai T; Yokota S; Nakao M; Nakazawa N; Taniwaki M; Kimura T; Sonoda Y; Kaneko H; Okuda T; Azuma H; Oka T; Takeda T; Watanabe A; Kikuta A; Asami K; Sekine I; Matsushita T; Tsuchiya T; Mimaya J; Koizumi S; Ohta S; Miyake M; Takaue Y; Iwai A; Fujimoto T
Cancer Res; 1998 Nov; 58(22):5182-7. PubMed ID: 9823330
[TBL] [Abstract][Full Text] [Related]
34. Expression of the fragile histidine triad gene in normal rat tissues and human kidney cancer cell lines.
Lee SH; Kim TJ; Kim HY; Kim JG; Park MK; Woo KM; Kim SH; Hwang KY; Nam HS; Min YK; Cho MH
Res Commun Mol Pathol Pharmacol; 2002; 112(1-4):145-57. PubMed ID: 15080505
[TBL] [Abstract][Full Text] [Related]
35. Comparative genomic mapping of the bovine Fragile Histidine Triad (FHIT) tumour suppressor gene: characterization of a 2 Mb BAC contig covering the locus, complete annotation of the gene, analysis of cDNA and of physiological expression profiles.
Uboldi C; Guidi E; Roperto S; Russo V; Roperto F; Di Meo GP; Iannuzzi L; Floriot S; Boussaha M; Eggen A; Ferretti L
BMC Genomics; 2006 May; 7():123. PubMed ID: 16719907
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis.
Bavi P; Jehan Z; Atizado V; Al-Dossari H; Al-Dayel F; Tulbah A; Amr SS; Sheikh SS; Ezzat A; El-Solh H; Uddin S; Al-Kuraya K
Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1708-18. PubMed ID: 16985034
[TBL] [Abstract][Full Text] [Related]
37. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.
Ishii H; Vecchione A; Furukawa Y; Sutheesophon K; Han SY; Druck T; Kuroki T; Trapasso F; Nishimura M; Saito Y; Ozawa K; Croce CM; Huebner K; Furukawa Y
Mol Cancer Res; 2003 Nov; 1(13):940-7. PubMed ID: 14638866
[TBL] [Abstract][Full Text] [Related]
38. Aberrant FHIT transcripts in Merkel cell carcinoma.
Sozzi G; Alder H; Tornielli S; Corletto V; Baffa R; Veronese ML; Negrini M; Pilotti S; Pierotti MA; Huebner K; Croce CM
Cancer Res; 1996 Jun; 56(11):2472-4. PubMed ID: 8653678
[TBL] [Abstract][Full Text] [Related]
39. Decreased or altered expression of the FHIT gene in human leukemias.
Sugimoto K; Yamada K; Miyagawa K; Hirai H; Oshimi K
Stem Cells; 1997; 15(3):223-8. PubMed ID: 9170214
[TBL] [Abstract][Full Text] [Related]
40. Positions of chromosome 3p14.2 fragile sites (FRA3B) within the FHIT gene.
Zimonjic DB; Druck T; Ohta M; Kastury K; Croce CM; Popescu NC; Huebner K
Cancer Res; 1997 Mar; 57(6):1166-70. PubMed ID: 9067288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
